DeJarnette departs IBM DIN-PACS team
DeJarnette Research Systems has decided to withdraw from the IBM consortium participating in the U.S. military's Digital Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) deal. The Towson, MD-based firm had been contributing its
DeJarnette Research Systems has decided to withdraw from the IBM consortium participating in the U.S. military's Digital Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) deal. The Towson, MD-based firm had been contributing its connectivity products to IBM as part of the team, but will no longer be involved in the engineering and product improvement plans on the project.
DeJarnette elected to withdraw from formal participation on the IBM team due to differences in corporate goals, technical direction, and business objectives between the two companies, said president Wayne DeJarnette. He declined to provide further details on the differences, other than to say that cultural differences between the companies led him to make the decision.
The company said that its decision will not affect its relationships with Department of Defense customers, however. The company anticipates it will contribute its products on an OEM basis to IBM and will continue to sell its products into other military accounts.
Although some analysts had estimated DIN-PACS spending to reach $165 million this year (PNN 6/98), actual awards to date have been under $35 million. This was not a factor in the decision to withdraw, however, DeJarnette said.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
